Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence

Respirology

Volumn 16, Issue 8, 2011, Pages 1210-1220

  Standfield, Lachlan ^a   Weston, Adaèle R ^a   Barraclough, Helen ^b   Van Kooten, Maximiliano ^b   Pavlakis, Nick ^c  

^a Health Technology Analysts Ltd   (Australia)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

histology cytology; lung cancer; pemetrexed; systematic review; treatment modifying effect

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MESNA; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VINCRISTINE;

CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; EVIDENCE-BASED MEDICINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TAXOIDS;

EID: 80155189584     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02025.x     Document Type: Review

References (49)

1. Hanson H, (ed.). Textbook of Lung Cancer, 2nd edn. Informa UK Ltd, London, 2008.
2. Hanna N, Shepherd FA, Fossella FV, et al,. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-97. (Pubitemid 41079796)
3. Scagliotti GV, Parikh P, Von Pawel J, et al,. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 3543-51.
4. Ciuleanu T, Brodowicz T, Zielinski C, et al,. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-40.
5. Scagliotti G, Hanna N, Fossella F, et al,. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-63.
6. Breathnach OS, Freidlin B, Conley B, et al,. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 2001; 19: 1734-42. (Pubitemid 32230875)
7. Pignon JP, Tribodet H, Scagliotti GV, et al,. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 2008; 26: 3552-9.
8. Ardizzoni A, Boni L, Tiseo M, et al,. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. 2007; 99: 847-57.
9. Hirsch FR, Spreafico A, Novello S, et al,. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J. Thorac. Oncol. 2008; 3: 1468-81.
10. Albain KS, Crowley JJ, LeBlanc M, et al,. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 1991; 9: 1618-26.
11. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
12. Aupérin A, Le Péchoux C, Pignon JP, et al,. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann. Oncol. 2006; 17: 473-83. (Pubitemid 43329586)
13. Burdett S, Burdett S, Stephens R, et al,. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 2008; 26: 4617-25.
14. Di Maio MD, Chiodini P, Georgoulias V, et al,. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2009; 27: 1836-43.
15. Comella P, Frasci G, Panza N, et al,. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the southern Italy cooperative oncology group. J. Clin. Oncol. 2000; 18: 1451-7. (Pubitemid 30205390)
16. Rudd RM, Gower NH, Spiro SG, et al,. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. 2005; 23: 142-53. (Pubitemid 41702633)
17. Kubota K, Kawahara M, Ogawara M, et al,. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008; 9: 1135-42.
18. Grønberg BH, Bremnes RM, Fløtten O, et al,. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2009; 27: 3217-24.
19. Kim ES, Hirsh V, Mok T, et al,. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18.
20. Cellerino R, Tummarello D, Guidi F, et al,. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J. Clin. Oncol. 1991; 9: 1453-61.
21. Billingham LJ, Cullen MH,. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann. Oncol. 2001; 12: 1671-5. (Pubitemid 34105655)
22. Pirker R, Pereira JR, Szczesna A, et al,. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31.
23. Herbst RS, Giaccone G, Schiller JH, et al,. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III triala-INTACT-2. J. Clin. Oncol. 2004; 22: 785-94. (Pubitemid 41103589)
24. Thatcher N, Chang A, Parikh P, et al,. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37. (Pubitemid 41540110)
25. Chang A, Parikh P, Thongprasert S, et al,. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J. Thorac. Oncol. 2006; 1: 847-55. (Pubitemid 47181391)
26. Lilenbaum R, Axelrod R, Thomas S, et al,. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol. 2008; 26: 863-9. (Pubitemid 351398077)
27. Crinò L, Scagliotti GV, Ricci S, et al,. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 1999; 17: 3522-30. (Pubitemid 29517923)
28. Krook JE, Jett JR, Fleming TR, et al,. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 1985; 3: 842-8. (Pubitemid 15062912)
29. Miller TP, Chen TT, Coltman CA Jr, et al,. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A southwest oncology group study. J. Clin. Oncol. 1986; 4: 502-8. (Pubitemid 16117939)
30. Tan E, Rolski J, Grodzki T, et al,. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2009; 20: 1249-56.
31. Shepherd FA, Pereira JR, Ciuleanu T, et al,. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123-32. (Pubitemid 41058344)
32. Georgoulias V, Papadakis E, Alexopoulos A, et al,. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-84. (Pubitemid 32488857)
33. Johnson JR, Cohen M, Sridhara R, et al,. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 2005; 11: 6414-21. (Pubitemid 41338977)
34. Georgoulias V, Samonis G, Papadakis E, et al,. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer. 2001; 34 (Suppl. 4): S47-51.
35. National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 181: pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE, London, England, July 2010. [Accessed 2 July 2010.] Available from URL
36. Herbst RS, Prager D, Hermann R, et al,. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 5892-9.
37. Giaccone G, Herbst RS, Manegold C, et al,. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III triala-INTACT 1. J. Clin. Oncol. 2004; 22: 777-84. (Pubitemid 41103588)
38. Giaccone G, Iacona RB, Fandi A, et al,. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009; 135: 467-76.
39. Maruyama R, Nishiwaki Y, Tamura T, et al,. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 4244-52.
40. Pao W, Iafrate AJ, Su Z,. Genetically informed lung cancer medicine. J. Pathol. 2011; 223: 230-40.
41. Martoni A, Marino A, Sperandi F, et al,. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur. J. Cancer. 2005; 41: 81-92. (Pubitemid 40029660)
42. Sculier JP, Lafitte JJ, Lecomte J, et al,. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann. Oncol. 2002; 13: 874-82. (Pubitemid 34752682)
43. Hoang T,. Does histology predict survival of advanced non-small cell lung cancer (NSCLC) treated with standard platin based chemotherapy? Retrospective analysis of E1594. Presented at the World Conference on Lung Cancer, July 31st to August 4th. 2009. San Francisco, USA. Abstract # PD6.4.1.
44. Sandler A, Kong G, Strickland D, et al,. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) Study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2008; 3 (Suppl. 4): S283. Abstract 133.
45. Gatzemeier U,. Impact of histology on response and survival in advanced non-small cell lung cancer (NSCLC)a-subset analysis of a phase III trial comparing two platinum-based doublets: i.v./oral vinorelbine (NVB) vs docetaxel (DTX). Presented at the World Conference on Lung Cancer, July 31st to August 4th. 2009. San Francisco, USA. Abstract # B2.5.
46. Chansky K,. Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy. Presented at the World Conference on Lung Cancer, July 31st to August 4th. 2009. San Francisco, USA. Abstract # B2.7.
47. Groen HJ,. Celecoxib in docetaxel/carboplatin treated patients (pts) with advanced non-small cell lung cancer (NSCLC): interaction of treatment with histology; a randomized placebo-controlled phase III study of the NVALT Group. Presented at the World Conference on Lung Cancer, July 31st to August 4th. 2009. San Francisco, USA. Abstract # D2.3.
48. Patel JD, Bonomi P, Socinski MA, et al,. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin. Lung Cancer 2009; 10: 252-6.
49. Zinner R, Saxman S, Peng G, et al,. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin. Lung Cancer. 2010; 11: 352-7.